Therasidbio
3 known investors
Korean biotech developing small-molecule drug candidates for nonalcoholic steatohepatitis and other digestive system disorders.
Also known as Therasid Bioscience · TheraSid Bioscience Co., Ltd.
Investors · 3
Company profile
researched Aug 2026TheraSid Bioscience Co., Ltd. is a Korean corporation engaged in bioscience research and development, founded in 2017 and headquartered in Gyeonggi-do, South Korea. It is profiled as a startup and holding company with a staff size in the 10-50 range, and is categorized in the pharmaceuticals and biotechnology industries.
The company's disclosed work centers on digestive system disorders and small-molecule drugs, with a focus on nonalcoholic steatohepatitis (NASH). Its pipeline includes three preclinical NASH candidates that it both originated and actively develops: TB-IH, TB-DK and TB-RB. A further candidate, TB-840, is described as an agonist of the retinoid-related orphan receptor alpha (RORalpha) being developed for NASH; TheraSid Bioscience sponsored a Phase 1 study of TB-840 (NCT05045534) that began on 14 September 2021 and is listed as completed.
Business model
TheraSid Bioscience develops proprietary small-molecule drug candidates in-house, originating and holding the active organization role for its pipeline programs and sponsoring its own clinical trials.
Traction
As of May 2025, the company's profile lists three preclinical NASH programs and one completed Phase 1 clinical trial, and a headcount in the 10-50 range.
▸Full profile — market position, technology, geography, history
Market position
An early-stage Korean drug developer whose most advanced disclosed asset has completed a Phase 1 study, with its remaining disclosed programs at the preclinical stage.
Technology
The company works on small-molecule therapeutics for digestive system disorders. Its clinical-stage candidate TB-840 is an oral agonist of RORalpha (retinoid-related orphan receptor), developed with target validation for RORalpha and its potential in NASH; the Phase 1 study assessed safety, tolerability and pharmacokinetics through single- and multiple-ascending oral doses in healthy subjects.
Geography
Headquartered in Gyeonggi-do, South Korea.
History
The company was established in 2017 and is based in Gyeonggi-do, South Korea. It has originated three preclinical candidates for nonalcoholic steatohepatitis (TB-IH, TB-DK and TB-RB) and advanced a further candidate, TB-840, into a Phase 1 study that started in September 2021 and has since been recorded as completed.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsTheraSid Bioscience began a dose block-randomized, double-blind, placebo-controlled, single-/multiple-ascending dose Phase 1 study evaluating safety, tolerability and pharmacokinetics of oral TB-840, a NASH treatment candidate acting as an RORalpha agonist, in healthy subjects. The trial is listed as completed, with 6 subjects per dose group assigned to TB-840 and 2 to placebo.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- TheraSid Bioscience Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapsesynapse.patsnap.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Therasidbio do?
- Korean biotech developing small-molecule drug candidates for nonalcoholic steatohepatitis and other digestive system disorders.
- Who are Therasidbio's investors?
- Therasidbio's investors include Aju IB Invesment Corporation, Kiwoom Investment, Solidus Investment.